NCT06837116

Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers

Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers: A Pilot Study

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Prince of Songkla University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Official title: Immunogenicity of an intradermal Qdenga vaccine among healthy volunteers: A pilot study

Detailed description

As in the setting of low- to middle-income countries, to demonstrating that lower doses of vaccine via intradermal route can still elicit robust immune responses, thereby lowering the overall cost of vaccination might be particularly meaningful ,with possible extra benefit of experiencing fewer side effects or risk of allergy. This study goal is to explores the potential of intradermal administration of Qdenga, hypothesizing that a lower dose via this route could achieve adequate immunogenicity compared to the standard subcutaneous administration, thus offering a cost-effective alternative particularly in low-resource settings where dengue is most prevalent.

Conditions

• Dengue

Interventions

Type	Name	Description
BIOLOGICAL	Vaccine	Subcutaneous route vs Intradermal route

Timeline

• Start date: 2025-04-19
• Primary completion: 2025-08-30
• Completion: 2025-09-30
• First posted: 2025-02-20
• Last updated: 2026-01-16
• Results posted: 2026-01-16

Locations

2 sites across 1 country: Thailand